ProstACT Update: TARGET Study Ethics Approval
Telix’s ProstACT TARGET Phase II clinical trial of prostate cancer antibody therapy candidate TLX591 has been granted Human Research Ethics Committee…
Read moreNews & Views
Telix Announces Licence Agreement with Lilly for Olaratumab
Telix announces a licence agreement for Lilly’s olaratumab antibody, for diagnosis and treatment of human…
Read more
PSMA-PET Imaging to be Funded through Medicare in Australia from July
Telix welcomes the listing of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) (PSMA-PET) imaging for patients with prostate cancer on the Medicare Benefits Schedule (MBS) from 1 July…
Read more
Telix, GMS and Monash Awarded $23M Federal Government Funding as part of $71M Australian Precision Medicine Enterprise (APME) Project
Telix announces that it is part of a $71.2 million Australian Precision Medicine Enterprise Project, which has been awarded $23 million in Federal Government…
Read more
Commercial Launch: Illuccix® Now Available to Order in the United States
Telix announces that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), also known as 68Ga-PSMA-11 injection, is now commercially available in the United…
Read more
2nd Joint Telix and Duchembio Symposium – Clinical Utility of PSMA PET Imaging in Prostate Cancer and Key PSMA PET Image Interpretation for Urologists
On World Theranostics Day, with our partner, Duchembio, we are pleased to present the 2nd joint symposium on the clinical utility of PSMA-PET in prostate cancer imaging and key PSMA…
Read more
Change of Composition of the Telix Board of Directors
Telix announces that Tiffany Olson has been appointed to the Board, as a U.S.-based independent Non-Executive…
Read more
New Video Series “PSMA PET/CT TODAY” Discusses the Future of Prostate Cancer Care with Leading Experts
Telix is pleased to announce the launch of PSMA PET/CT Today, a five-part video series, featuring leading theranostics experts, on the role of advanced diagnostic imaging in prostate cancer…
Read more
Telix Granted FDA Orphan Drug Designation for Bone Marrow Conditioning Treatment
Telix announces that the FDA has granted Orphan Drug Designation for TLX66 (90Y-besilesomab), for conditioning treatment prior to hematopoietic stem cell transplant…
Read more
Telix and Xiel Sign U.K. and Ireland Distribution Agreement for Illuccix®
Telix announces agreement with Xiel for the distribution of Telix’s prostate cancer investigational imaging product, Illuccix® in the UK and Republic of…
Read more